Select Publications

Journal articles

Swift C; Katelaris AL; Tiqui TB; Smith J; Papa T; Janz-Robinson E; Nguyen T; Wang Q; Draper J; Sintchenko V; Marriott DJE; Sheppeard V, 2024, 'Toxigenic cutaneous diphtheria without recent travel, Sydney, Australia, 2022', Medical Journal of Australia, 220, pp. 126 - 128, http://dx.doi.org/10.5694/mja2.52190

Carland JE; Stojanova J; Lau C; Day RO; Marriott DJE, 2024, 'Crying Over Stark Differences: Resource Disparity and Therapeutic Drug Monitoring.', Ther Drug Monit, http://dx.doi.org/10.1097/FTD.0000000000001185

Neoh CF; Chen SCA; Kong DCM; Hamilton K; Nguyen QA; Spelman T; Tew M; Harvey EL; Ho SA; Saunders NR; Tennakoon S; Crowe A; Marriott D; Trubiano JA; Slavin MA, 2024, 'Costs associated with invasive Scedosporium and Lomentospora prolificans infections: a case-control study', Journal of Antimicrobial Chemotherapy, 79, pp. 46 - 54, http://dx.doi.org/10.1093/jac/dkad345

Robosa RS; Lau C; Stojanova J; Chin CW; Marriott DJE, 2023, 'Ceftazidime Plasma Concentrations and Neurotoxicity: The Importance of Therapeutic Drug Monitoring in Patients Undergoing Different Modalities of Renal Replacement Therapy. A Grand Round', Therapeutic Drug Monitoring, 45, pp. 711 - 713, http://dx.doi.org/10.1097/FTD.0000000000001124

Burrows FS; Carlos LM; Stojanova J; Marriott DJE, 2023, 'It cuts both ways: A single-center retrospective review describing a three-way interaction between flucloxacillin, voriconazole and tacrolimus', International Journal of Antimicrobial Agents, 62, http://dx.doi.org/10.1016/j.ijantimicag.2023.106908

Lau C; Marriott D; Bui J; Figtree M; Gould M; Chubaty A; Su Y; Adhikari S; Konecny P; Kozierowski K; Holland T; Milliken E; Akram A; Mcnamara A; Sun Y; Van Hal S; Patanwala AE; Shahabi-Sirjani A; Gray T; Yeo CY; Netluch A; Halena S; Appay M; Alameddine R; Yin F; Nguyen Q; So MY; Sandaradura I; Kim HY; Galimam S; Cerruto N; Lai T; Gilbey T; Daveson K; Reuter SE; Penm J; Alffenaar JW, 2023, 'LInezolid Monitoring to MInimise Toxicity (LIMMIT1): A multicentre retrospective review of patients receiving linezolid therapy and the impact of therapeutic drug monitoring', International Journal of Antimicrobial Agents, 61, http://dx.doi.org/10.1016/j.ijantimicag.2023.106783

Seah V; Sreeharan T; Kocic D; Reuter SE; Girgis L; Marriott DJE; Stocker SL, 2023, 'Effect of Therapeutic Plasma Exchange on Itraconazole Pharmacokinetics: A Case Study', Therapeutic Drug Monitoring, 45, pp. 129 - 132, http://dx.doi.org/10.1097/FTD.0000000000001057

Burrows FS; Carlos LM; Stojanova J; Marriott D, 2023, 'It Cuts Both Ways: Single-Center Retrospective Review Describing Three-Way Interaction Between Flucloxadllin, Voriconazole and Tacrolimus', JOURNAL OF HEART AND LUNG TRANSPLANTATION, 42, pp. S500 - S500, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000992480601388&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Keighley C; Pope AL; Marriott D; Chen SCA; Slavin MA, 2023, 'Time-to-positivity in bloodstream infection for Candida species as a prognostic marker for mortality', Medical Mycology, 61, http://dx.doi.org/10.1093/mmy/myad028

Marriott DJE; Cattaneo D, 2023, 'Why Product Information Should not be Set in Stone: Lessons from a Decade of Linezolid Therapeutic Drug Monitoring: An Opinion Paper', Therapeutic Drug Monitoring, 45, pp. 209 - 216, http://dx.doi.org/10.1097/FTD.0000000000001088

Neoh CF; Chen SCA; Crowe A; Hamilton K; Nguyen QA; Marriott D; Trubiano JA; Spelman T; Kong DCM; Slavin MA, 2023, 'Invasive Scedosporium and Lomentospora prolificans Infections in Australia: A Multicenter Retrospective Cohort Study', Open Forum Infectious Diseases, 10, http://dx.doi.org/10.1093/ofid/ofad059

Cattaneo D; Marriott DJE; Gervasoni C, 2023, 'Hematological toxicities associated with linezolid therapy in adults: key findings and clinical considerations', Expert Review of Clinical Pharmacology, 16, pp. 219 - 230, http://dx.doi.org/10.1080/17512433.2023.2181160

Abbott A; Karas P; Mirdad F; Marriott D; Malouf M; Plit M; Darley D, 2023, '(676) Prevalence, Risk Factors and Outcomes for Scedosporium and Lomentospora spp. Following Lung Transplantation at a Single Australian Centre', The Journal of Heart and Lung Transplantation, 42, pp. S300 - S300, http://dx.doi.org/10.1016/j.healun.2023.02.690

Li J; Lau C; Anderson N; Burrows F; Mirdad F; Carlos L; Pitman AJ; Muthiah K; Darley DR; Andresen D; Macdonald P; Marriott D; Dharan NJ, 2022, 'Multispecies Outbreak of Nocardia Infections in Heart Transplant Recipients and Association with Climate Conditions, Australia', Emerging Infectious Diseases, 28, pp. 2155 - 2164, http://dx.doi.org/10.3201/eid2811.220262

Hou J; Marriott D; Cattaneo D; Stocker S; Stojanova J; Alffenaar JW; Xiao C; Zhao Y; Gong H; Yan M, 2022, 'Therapeutic drug monitoring practices of anti-infectives: An Asia-wide cross-sectional survey', Frontiers in Pharmacology, 13, http://dx.doi.org/10.3389/fphar.2022.992354

Shivasabesan G; Logan B; Brennan X; Lau C; Vaze A; Bennett M; Gorrie N; Mirdad F; Deveza R; Koo CM; Mccluskey P; Macdonald P; Marriott D; Muthiah K; Dharan NP, 2022, 'Disseminated Aspergillus lentulus Infection in a Heart Transplant Recipient: A Case Report', Clinical Infectious Diseases, 75, pp. 1235 - 1238, http://dx.doi.org/10.1093/cid/ciac205

Hsu H; Seah V; Marriott D; Moore J, 2022, 'Enterococcus cecorum infective endocarditis in a patient with chronic myeloid leukaemia and cirrhosis', Pathology, 54, pp. 495 - 497, http://dx.doi.org/10.1016/j.pathol.2021.07.004

Margineanu I; Akkerman O; Cattaneo D; Goletti D; Marriott DJE; Migliori GB; Mirzayev F; Peloquin CA; Stienstra Y; Alffenaar JW, 2022, 'Practices of therapeutic drug monitoring in tuberculosis: an international survey', European Respiratory Journal, 59, http://dx.doi.org/10.1183/13993003.02787-2021

Sandaradura I; Alffenaar JW; Cotta MO; Daveson K; Day RO; Van Hal S; Lau C; Marriott DJE; Penm J; Roberts JA; Tabah A; Williams P; Imani S, 2022, 'Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: Availability, performance and barriers to implementation', British Journal of Clinical Pharmacology, 88, pp. 669 - 679, http://dx.doi.org/10.1111/bcp.14995

Reuter SE; Stocker SL; Alffenaar JWC; Baldelli S; Cattaneo D; Jones G; Koch BCP; Kocic D; Mathew SK; Molinaro M; Neely M; Sandaradura I; Marriott DJE, 2022, 'Optimal Practice for Vancomycin Therapeutic Drug Monitoring: Position Statement from the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology', Therapeutic Drug Monitoring, 44, pp. 121 - 132, http://dx.doi.org/10.1097/FTD.0000000000000944

Marriott DJE; Cattaneo D, 2022, 'Special Issue on the Therapeutic Drug Monitoring of Anti-infective Drugs: Editorial', Therapeutic Drug Monitoring, 44, pp. 1 - 2, http://dx.doi.org/10.1097/FTD.0000000000000951

Cattaneo D; Falcone M; Gervasoni C; Marriott DJE, 2022, 'Therapeutic Drug Monitoring of Antibiotics in the Elderly: A Narrative Review', Therapeutic Drug Monitoring, 44, pp. 75 - 85, http://dx.doi.org/10.1097/FTD.0000000000000939

Kim HY; Baldelli S; Märtson AG; Stocker S; Alffenaar JW; Cattaneo D; Marriott DJE, 2022, 'Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology', Therapeutic Drug Monitoring, 44, pp. 198 - 214, http://dx.doi.org/10.1097/FTD.0000000000000931

Lau C; Marriott D; Schultz HB; Gould M; Andresen D; Wicha SG; Alffenaar JW; Penm J; Reuter SE, 2021, 'Assessment of cefepime toxicodynamics: comprehensive examination of pharmacokinetic/pharmacodynamic targets for cefepime-induced neurotoxicity and evaluation of current dosing guidelines', International Journal of Antimicrobial Agents, 58, http://dx.doi.org/10.1016/j.ijantimicag.2021.106443

Carland JE; Stocker SL; Baysari MT; Li C; Själin J; Moran MA; Tang S; Sandaradura I; Elhage T; Gilbey T; Williams KM; Marriott DJE; Day RO, 2021, 'Are vancomycin dosing guidelines followed? A mixed methods study of vancomycin prescribing practices', British Journal of Clinical Pharmacology, 87, pp. 4221 - 4229, http://dx.doi.org/10.1111/bcp.14834

Chau MM; Daveson K; Alffenaar JWC; Gwee A; Ho SA; Marriott DJE; Trubiano JA; Zhao J; Roberts JA; Chang CC; Blyth CC; Chen SCA; Khanina A; Morrissey CO; Thursky KA; Worth L; Slavin MA, 2021, 'Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021', Internal Medicine Journal, 51, pp. 37 - 66, http://dx.doi.org/10.1111/imj.15587

Imani S; Buscher H; Day R; Gentili S; Jones GRD; Marriott D; Norris R; Sandaradura I, 2021, 'Correction to: An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric β-lactam therapy (European Journal of Clinical Microbiology & Infectious Diseases, (2018), 37, 11, (2171-2175), 10.1007/s10096-018-3357-9)', European Journal of Clinical Microbiology and Infectious Diseases, 40, pp. 1789, http://dx.doi.org/10.1007/s10096-021-04291-6

Uster DW; Stocker SL; Carland JE; Brett J; Marriott DJE; Day RO; Wicha SG, 2021, 'A Model Averaging/Selection Approach Improves the Predictive Performance of Model-Informed Precision Dosing: Vancomycin as a Case Study (vol 109, pg 175, 2021)', CLINICAL PHARMACOLOGY & THERAPEUTICS, 110, pp. 1401 - 1401, http://dx.doi.org/10.1002/cpt.2353

Sandaradura I; Marriott DJE; Day RO; Norris RLG; Pang E; Stocker SL; Reuter SE, 2021, 'Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy', European Journal of Clinical Microbiology and Infectious Diseases, 40, pp. 1521 - 1528, http://dx.doi.org/10.1007/s10096-021-04201-w

Märtson AG; Boonstra JM; Sandaradura I; Kosterink JGW; van der Werf TS; Marriott DJE; Zijlstra JG; Touw DJ; Alffenaar JWC, 2021, 'Reply to Van Daele et al., “Fluconazole underexposure in critically ill patients: A matter of using the right targets?”', Antimicrobial Agents and Chemotherapy, 65, http://dx.doi.org/10.1128/AAC.00465-21

Alffenaar JW; Märtson AG; Heysell SK; Cho JG; Patanwala A; Burch G; Kim HY; Sturkenboom MGG; Byrne A; Marriott D; Sandaradura I; Tiberi S; Sintchencko V; Srivastava S; Peloquin CA, 2021, 'Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections', Clinical Pharmacokinetics, 60, pp. 711 - 725, http://dx.doi.org/10.1007/s40262-021-01000-6

Marriott D; Beresford R; Mirdad F; Stark D; Glanville A; Chapman S; Harkness J; Dore GJ; Andresen D; Matthews GV, 2021, 'Concomitant Marked Decline in Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Other Respiratory Viruses among Symptomatic Patients Following Public Health Interventions in Australia: Data from St Vincent's Hospital and Associated Screening Clinics, Sydney, NSW', Clinical Infectious Diseases, 72, pp. E649 - E651, http://dx.doi.org/10.1093/cid/ciaa1256

Meredith T; Dharan N; Killen L; Anandabaskaran S; Kim A; Yang T; Marriott D; Hayward C; Macdonald P, 2021, 'Colonic malakoplakia in a dual stem cell and cardiac transplant recipient: A case report and literature review', Transplant Infectious Disease, 23, http://dx.doi.org/10.1111/tid.13488

Iglesias CPK; Schnegg B; Dharan N; Lao C; Joseph J; Marriott D; Hayward C, 2021, 'LVAD- Antibiotic and Warfarin Alert', JOURNAL OF HEART AND LUNG TRANSPLANTATION, 40, pp. S523 - S523, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000631254401561&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ryan AC; Carland JE; McLeay RC; Lau C; Marriott DJE; Day RO; Stocker SL, 2021, 'Evaluation of amikacin use and comparison of the models implemented in two Bayesian forecasting software packages to guide dosing', British Journal of Clinical Pharmacology, 87, pp. 1422 - 1431, http://dx.doi.org/10.1111/bcp.14542

Sandaradura I; Wojciechowski J; Marriott DJE; Day RO; Stocker S; Reuter SE, 2021, 'Model-optimized fluconazole dose selection for critically ill patients improves early pharmacodynamic target attainment without the need for therapeutic drug monitoring', Antimicrobial Agents and Chemotherapy, 65, http://dx.doi.org/10.1128/AAC.02019-20

Boonstra JM; Märtson AG; Sandaradura I; Kosterink JGW; van der Werf TS; Marriott DJE; Zijlstra JG; Touw DJ; Alffenaar JWC, 2021, 'Optimization of fluconazole dosing for the prevention and treatment of invasive candidiasis based on the pharmacokinetics of fluconazole in critically ill patients', Antimicrobial Agents and Chemotherapy, 65, http://dx.doi.org/10.1128/AAC.01554-20

Keighley CL; Pope A; Marriott DJE; Chapman B; Bak N; Daveson K; Hajkowicz K; Halliday C; Kennedy K; Kidd S; Sorrell TC; Underwood N; van Hal S; Slavin MA; Chen SCA, 2021, 'Risk factors for candidaemia: A prospective multi-centre case-control study', Mycoses, 64, pp. 257 - 263, http://dx.doi.org/10.1111/myc.13211

Carland JE; Elhage T; Baysari MT; Stocker SL; Marriott DJE; Taylor N; Day RO, 2021, 'Would they trust it? An exploration of psychosocial and environmental factors affecting prescriber acceptance of computerised dose-recommendation software', British Journal of Clinical Pharmacology, 87, pp. 1215 - 1233, http://dx.doi.org/10.1111/bcp.14496

Uster DW; Stocker SL; Carland JE; Brett J; Marriott DJE; Day RO; Wicha SG, 2021, 'A Model Averaging/Selection Approach Improves the Predictive Performance of Model-Informed Precision Dosing: Vancomycin as a Case Study', Clinical Pharmacology and Therapeutics, 109, pp. 175 - 183, http://dx.doi.org/10.1002/cpt.2065

Stocker SL; Carland JE; Reuter SE; Stacy AE; Schaffer AL; Stefani M; Lau C; Kirubakaran R; Yang JJ; Shen CFJ; Roberts DM; Marriott DJE; Day RO; Brett J, 2021, 'Evaluation of a Pilot Vancomycin Precision Dosing Advisory Service on Target Exposure Attainment Using an Interrupted Time Series Analysis', Clinical Pharmacology and Therapeutics, 109, pp. 212 - 221, http://dx.doi.org/10.1002/cpt.2113

Imani S; Alffenaar JW; Cotta MO; Daveson K; van Hal S; Lau C; Marriott D; Penm J; Roberts JA; Tabah A; Trethewy N; Williams P; Sandaradura I, 2020, 'Therapeutic drug monitoring of commonly used anti-infective agents: A nationwide cross-sectional survey of Australian hospital practices', International Journal of Antimicrobial Agents, 56, http://dx.doi.org/10.1016/j.ijantimicag.2020.106180

Zeitlinger M; Koch BCP; Bruggemann R; De Cock P; Felton T; Hites M; Le J; Luque S; MacGowan AP; Marriott DJE; Muller AE; Nadrah K; Paterson DL; Standing JF; Telles JP; Wölfl-Duchek M; Thy M; Roberts JA, 2020, 'Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents', Clinical Pharmacokinetics, 59, pp. 1195 - 1216, http://dx.doi.org/10.1007/s40262-020-00924-9

Märtson AG; Sturkenboom MGG; Stojanova J; Cattaneo D; Hope W; Marriott D; Patanwala AE; Peloquin CA; Wicha SG; van der Werf TS; Tängdén T; Roberts JA; Neely MN; Alffenaar JWC, 2020, 'How to design a study to evaluate therapeutic drug monitoring in infectious diseases?', Clinical Microbiology and Infection, 26, pp. 1008 - 1016, http://dx.doi.org/10.1016/j.cmi.2020.03.008

Watson S; Rozzoli K; Keogh A; Ahlston E; Scroop G; Marriott D; Fallon K; Grossman J; Allen T; Milliken E; Kidd R, 2020, 'In Honour of Professor Cristobal dos Remedios on behalf of the MAWA Trust', Biophysical Reviews, 12, pp. 765 - 766, http://dx.doi.org/10.1007/s12551-020-00746-w

Chaudhri K; Stocker SL; Williams KM; McLeay RC; Marriott DJE; Di Tanna GL; Day RO; Carland JE, 2020, 'Voriconazole: An audit of hospital-based dosing and monitoring and evaluation of the predictive performance of a dose-prediction software package', Journal of Antimicrobial Chemotherapy, 75, pp. 1981 - 1984, http://dx.doi.org/10.1093/jac/dkaa098

Abdul-Aziz MH; Alffenaar JWC; Bassetti M; Bracht H; Dimopoulos G; Marriott D; Neely MN; Paiva JA; Pea F; Sjovall F; Timsit JF; Udy AA; Wicha SG; Zeitlinger M; De Waele JJ; Roberts JA, 2020, 'Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#', Intensive Care Medicine, 46, pp. 1127 - 1153, http://dx.doi.org/10.1007/s00134-020-06050-1

Cattaneo D; Corona A; De Rosa FG; Gervasoni C; Kocic D; Marriott DJ, 2020, 'The management of anti-infective agents in intensive care units: the potential role of a ‘fast’ pharmacology', Expert Review of Clinical Pharmacology, 13, pp. 355 - 366, http://dx.doi.org/10.1080/17512433.2020.1759413

Sandaradura I; Goeman E; Pontivivo G; Fine E; Gray H; Kerr S; Marriott D; Harkness J; Andresen D, 2020, 'A close shave? Performance of P2/N95 respirators in healthcare workers with facial hair: results of the BEARDS (BEnchmarking Adequate Respiratory DefenceS) study', Journal of Hospital Infection, 104, pp. 529 - 533, http://dx.doi.org/10.1016/j.jhin.2020.01.006

Lau C; Marriott D; Gould M; Andresen D; Reuter SE; Penm J, 2020, 'A retrospective study to determine the cefepime-induced neurotoxicity threshold in hospitalized patients', Journal of Antimicrobial Chemotherapy, 75, pp. 718 - 725, http://dx.doi.org/10.1093/jac/dkz476


Back to profile page